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Abstract
The importance of 1,5-anhydroglucitol (1,5-AG) as an intermediate biomarker
for diabetic pregnancy is multi-fold: (1) it serves as a reliable indicator of
moderate-level glycemic control, especially during early gestation; (2) it has
been associated with increased risk of diabetes, independent of HbA1c and
fasting glucose; and (3) it is an independent risk factor for the development
of eclampsia during pregnancy. However, the clinical use of this biomarker
during pregnancy has been underutilized due to physiological changes in
glomerular filtration rate, plasma volume, and other hemodynamic parameters
which have been hypothesized to bias gestational serum 1,5-AG concentra-
tions. Here, we develop an in-silico model of gestational 1,5-AG by combining
pre-existing physiological data in the literature with a two-compartment
mathematical model, building off of a previous kinetic model described by
Stickle and Turk (1997) Am. J. Physiol., 273, E821. Our model quantitatively
characterizes how renal and hemodynamic factors impact measured 1,5-AG
during normal pregnancy and during pregnancy with gestational diabetes and
diabetes mellitus. During both normal and diabetic pregnancy, we find that a
simple two-compartment model of 1,5-AG kinetics, with all parameters but
reabsorption fraction adjusted for time in pregnancy, efficiently models
1,5-AG kinetics throughout the first two trimesters. Allowing reabsorption
fraction to decrease after 25 weeks permits parameters closer to expected
physiological values during the last trimester. Our quantitative model of
1,5-AG confirms the involvement of hypothesized renal and hemodynamic
mechanisms during pregnancy, clarifying the expected trends in 1,5-AG to aid
clinical interpretation. Further research and data may elucidate biological
changes during the third trimester that account for the drop in 1,5-AG con-
centrations, and clarify physiological differences between diabetes subtypes
during pregnancy.
Introduction
The treatment and monitoring of diabetes relies on tight
monitoring of glycemic control by measuring biomarkers
in the body (The Diabetes Control and Complications
Trial Research Group, 1993; UK Prospective Diabetes
Study (UKPDS) Group, 1998a; UK Prospective Diabetes
Study (UKPDS) Group, 1998b). Clinically, there are two
common biomarkers that are used to measure glycemic
control: daily glucose monitoring and HbA1c. Plasma glu-
cose levels reflect an instantaneous, short-term measure of
glycemic control while HbA1c levels provide insight on
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long-term glycemic control, averaged over 3–4 months
(Buse et al. 2003). According to the Diabetes Control and
Complications Trial group, mean HbA1c does not fully
capture glycemic control since it is a long-term measure;
rather, “complications may be more highly dependent on
the extent of postprandial glycemic excursions” (The Dia-
betes Control and Complications Trial Research Group,
1995). More recently, studies indicate that measures of
intermediate-term glycemic control, specifically those
reflective of postprandial glucose fluctuations, are inde-
pendent risk factors for the development of macrovascu-
lar complications (Hanefeld et al. 1996; Muggeo et al.
2000; Temelkova-Kurktschiev et al. 2000; Dungan et al.
2006). Thus, used in parallel to short-term and long-term
measures of glycemic control, an intermediate-term bio-
marker that is indicative of postprandial glucose excur-
sions may be useful in the management of patients with
diabetes and informative of the risk of macrovascular
complications.
The polyol 1,5-anhydroglucitol (1,5-AG), quantifiable
in plasma and cerebrospinal fluid, is a molecule of signifi-
cant interest in the assessment of diabetes mellitus that
has been proposed as a marker for postprandial hyper-
glycemia. 1,5-AG intake is mainly through ingestion (av-
erage of 5 mg daily) (McGill et al. 2004) and the major
route of elimination is through urinary excretion, with
intake and elimination at approximate equilibrium. Nor-
mally, 1,5-AG is filtered in the kidneys and completely
reabsorbed in the renal tubules back into the bloodstream
(Buse et al. 2003), leading to a stable 1,5-AG plasma con-
centration of ~ 20 mg/mL (Mehta et al. 2012). However,
with elevated serum glucose concentrations (>180 lmol/
L), plasma 1,5-AG levels fall due to competitive inhibition
of renal reabsorption by glucose. Thus, decreased plasma
concentrations of 1,5-AG are observed in diabetes, sec-
ondary to competitive tubular reabsorption of 1,5-AG
with hyperglycemia (Sermer et al. 1998). 1,5-AG levels
recover within 24–72 h posthyperglycemia (Yamanouchi
et al. 1992, 1996), reflecting even transient elevations of
glucose within the past few days and thereby serving as a
measurement which is informative of glycemic excursions
even in patients with normal HbA1cs (Kishimoto et al.
1995). Indeed, 1,5-AG has been associated with risk of
developing diabetes independently of HbA1c and fasting
glucose concentrations (Juraschek et al. 2012).
While intermediate-term biomarkers of glycemic con-
trol such as 1,5-AG may be useful to monitor diabetes in
the general population, they are even more critical in ges-
tational diabetes mellitus (GDM) and diabetes mellitus
(DM) during pregnancy — diseases complicating greater
than 17% of pregnancies (Sacks et al. 2012). Due to the
3–4 month timeline by which HbA1c levels fluctuate,
HbA1c does not optimally capture intermediate-term
glycemic excursions during the critical 9 month period of
gestation. Although an automated enzymatic assay (Gly-
comark) has been approved in the U.S. to measure
plasma 1,5-AG levels (McGill et al. 2004), and a similar
assay has been used in Japan for over two decades (Fuku-
mura et al. 1994), some studies do not recommend moni-
toring 1,5-AG for glycemic control during pregnancy,
since physiological changes in glomerular filtration rate,
plasma volume, and other hemodynamic parameters dur-
ing gestation may bias 1,5-AG concentrations in the
blood (Kilpatrick et al. 1999; Tam et al. 2001). Nonethe-
less, several studies have suggested that 1,5-AG concentra-
tions during pregnancy are reliable indicators of
moderate-term glycemic control, especially during early
stages of pregnancy (Yamanouchi et al. 1996; Buse et al.
2003; Dworacka et al. 2006; Andronesi et al. 2012; Boritza
et al. 2014). Moreover, multiple studies have suggested
postprandial glucose to be an independent risk factor for
the development of pre-eclampsia and eclampsia during
later stages of pregnancy (Sermer et al. 1998; Rowan et al.
2010). Thus, while an intermediate-term biomarker of
hyperglycemic excursions may be clinically beneficial in
informing risk and motivating improved monitoring and
prevention of such vascular disease (Fukumura et al.
1994), a quantitative understanding of the physiological
parameters impacting 1,5-AG baseline dynamics during
pregnancy has not been sufficient to allow transformation
of 1,5-AG into a meaningful parameter in the context
of the renal and hemodynamic changes that occur in
pregnancy.
Here, we develop an in-silico model of 1,5-AG during
pregnancy. By using published data and applying it to
a two-compartment mathematical model, we are
attempting to more precisely characterize 1,5-AG physi-
ological behavior in the context of renal and hemody-
namic parameters for the monitoring of GDM and DM
during pregnancy. We use the original compartment
model for 1,5-AG by Stickle and Turk (Stickle and
Turk 1997) and adapt the model for diabetes in preg-
nant populations by accounting for physiologic changes
in GFR, reabsorption fraction, plasma volume, and frac-
tional plasma mass. One limitation of the study is the
paucity of available data on GFR, plasma volume, and
fractional plasma mass; as such, we were unable to dis-
tinguish between normal individuals and different dia-
betic subtypes with respect to these baseline
hemodynamic and renal parameters during the gesta-
tional timeline. We hope that providing a mathematical
context can shed light onto the physiological mecha-
nisms that have been hypothesized to impact gestational
1,5-AG dynamics and motivate further research to
improve understanding of 1,5-AG during pregnancy,
decreasing the barrier to clinical use of this biomarker.
2017 | Vol. 5 | Iss. 16 | e13375
Page 2
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society
A Computational Model of 1,5-AG Dynamics During Pregnancy S. M. Zekavat et al.
T
a
b
le
1
.
Su
m
m
ar
y
o
f
th
e
m
o
d
el
.
Pa
ra
m
et
er
D
es
cr
ip
ti
o
n
U
n
it
s
R
ep
re
se
n
ta
ti
o
n
in
m
o
d
el
A
ve
ra
g
e
st
an
d
ar
d
d
ev
ia
ti
o
n
1
Im
p
le
m
en
ta
ti
o
n
o
f
D
at
a
D
at
a
so
u
rc
e
t p
re
g
Ti
m
e
d
u
ri
n
g
p
re
g
n
an
cy
D
ay
s
t p
re
g
–
–
–
G
FR
(t
p
re
g
)
G
lo
m
er
u
la
r
fi
lt
ra
ti
o
n
ra
te
m
L/
d
ay
0
:0
7
7
t
p
re
g
2
þ
4
:1
7
t
p
re
g
þ
9
9
:0
4
2
1
.2
U
se
d
d
at
a
to
ca
lc
u
la
te
fi
t
in
Fi
g
u
re
2
(n
=
2
5
,
n
o
rm
al
p
re
g
n
an
cy
)
D
u
n
lo
p
(1
9
8
1
)
V
p
la
sm
a
(t
p
re
g
)
Pl
as
m
a
vo
lu
m
e
m
L
7
9
6
:2
0
:6
2
þ
4
:4
e
ð0
:2
1
ð
t p
re
g
9
:2
ÞÞ
þ
2
3
7
8
5
2
.3
U
se
d
d
at
a
to
ca
lc
u
la
te
fi
t
in
Fi
g
u
re
2
(n
=
5
2
to
6
8
,
n
o
rm
al
p
re
g
n
an
cy
)
W
h
it
ta
ke
r
an
d
Li
n
d
(1
9
9
3
)
f1
;5
A
G
p
la
sm
a
ðt p
re
g
Þ
Fr
ac
ti
o
n
al
p
la
sm
a
m
as
s
U
n
it
le
ss
0
.0
0
6
*t
p
re
g
+
0
.3
0
.1
2
U
se
d
d
at
a
to
ca
lc
u
la
te
fi
t
in
Fi
g
u
re
2
(n
=
2
7
,
n
o
rm
al
p
re
g
n
an
cy
)
Pi
p
e
et
al
.
(1
9
7
9
)
k i
1
,5
-A
G
in
p
u
t
ra
te
m
g
/d
ay
5
–
U
se
d
d
at
a
in
O
D
E
St
ic
kl
e
an
d
Tu
rk
(1
9
9
7
)
[G
]
M
ea
n
m
ax
im
al
g
lu
co
se
co
n
ce
n
tr
at
io
n
m
M
\
7
:5
m
M
fo
r
n
o
rm
al
p
re
g
n
an
ci
es
8
:9
m
M
fo
r
G
D
M
/D
M
p
re
g
n
an
ci
es

–
U
se
d
ra
w
va
lu
es
in
m
o
d
el
N
o
w
ak
et
al
.
(2
0
1
3
)
r(
[G
])
R
ea
b
so
rp
ti
o
n
fr
ac
ti
o
n
U
n
it
le
ss
0
:9
9
8
4
if
½G
\
7
:4
m
M
ð
0
:0
0
2
6
m
M
1
Þ
½G
þ
1
:0
1
8
if
½G
[
7
:4
m
M

–
U
se
d
eq
u
at
io
n
fo
r
r
es
ti
m
at
io
n
St
ic
kl
e
an
d
Tu
rk
(1
9
9
7
)
r(
t p
re
g
,
[G
])
R
ea
b
so
rp
ti
o
n
fr
ac
ti
o
n
U
n
it
le
ss
Fo
r
½G
\
7
:4
m
M
:
a
if
t p
re
g

2
5
w
ee
ks
a

b
ð
t p
re
g

2
5
Þi
f
t p
re
g
[
2
5
w
ee
ks

Fo
r
½G
[
7
:4
m
M
:
a

c½G
if
t p
re
g

2
5
w
ee
ks
a

b
ð
t p
re
g

2
5
Þ
c½G
if
t p
re
g
[
2
5
w
ee
ks

w
h
er
e
a
an
d
b
re
fe
r
to
b
es
t-
fi
tt
ed
va
lu
es
fr
o
m
Fi
g
u
re
4
–
U
se
d
1
,5
-A
G
d
at
a
to
es
ti
m
at
e
b
es
t-
fi
tt
ed
a
an
d
b
fo
r
an
al
te
rn
at
iv
e
r
es
ti
m
at
io
n
d
u
ri
n
g
p
re
g
n
an
cy
ti
m
el
in
e
Te
ts
u
o
et
al
.
(1
9
9
0
)
Th
e
st
at
ed
p
ar
am
et
er
s
w
er
e
u
se
d
in
an
o
rd
in
ar
y
d
if
fe
re
n
ti
al
eq
u
at
io
n
(O
D
E)
to
fi
n
d
1
,5
-A
G
le
ve
ls
.
Fo
r
ea
ch
va
lu
e
o
f
t p
re
g
ex
am
in
ed
,
th
e
O
D
E
w
as
u
se
d
to
fi
n
d
th
e
co
rr
es
p
o
n
d
in
g
st
ea
d
y
st
at
e
le
ve
l
o
f
1
,5
-A
G
.
Th
is
in
fo
rm
at
io
n
w
as
co
m
p
ile
d
fo
r
m
an
y
va
lu
es
o
f
t p
re
g
to
p
ro
vi
d
e
an
o
ve
ra
ll
p
ic
tu
re
o
f
h
o
w
1
,5
-A
G
le
ve
ls
ch
an
g
e
th
ro
u
g
h
o
u
t
p
re
g
n
an
cy
.
1
A
ve
ra
g
e
st
an
d
ar
d
d
ev
ia
ti
o
n
s
ac
ro
ss
al
l
av
ai
la
b
le
ti
m
e
p
o
in
ts
vi
su
al
iz
ed
in
Fi
g
u
re
2
ar
e
re
p
o
rt
ed
fo
r
ea
ch
p
ar
am
et
er
(f
o
r
fr
ac
ti
o
n
al
p
la
sm
a
m
as
s,
th
e
st
an
d
ar
d
d
ev
ia
ti
o
n
s
ar
e
av
er
ag
ed
fo
r
th
e
th
re
e
ti
m
e
p
o
in
ts
d
u
ri
n
g
p
re
g
n
an
cy
,
ex
cl
u
d
in
g
w
ee
k
0
).
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society
2017 | Vol. 5 | Iss. 16 | e13375
Page 3
S. M. Zekavat et al. A Computational Model of 1,5-AG Dynamics During Pregnancy
Methods
Compartment model for
1,5-Anhydroglucitol
Steady-state two-compartment (plasma and tissue) mass
balance models for the presence of 1,5-AG in plasma have
been validated by Yamanouchi et al. (1991) and Stickle
and Turk (1997). Here, we describe an extension of this
two-compartment model towards normal pregnancy and
toward pregnancy with diabetes. As previously noted, the
paucity of existing data limits our ability to distinguish
between different diabetic subtypes during pregnancy.
Our two-compartment model (Fig. 1) describes 1,5-AG
dynamics in plasma and tissue over timeline in pregnancy
tpreg, assuming rapid partitioning between plasma and tis-
sue pools. We describe the concentration of 1,5-AG in
plasma over time (t, representing time to steady-state)
and over timeline in pregnancy (tpreg), as in the differen-
tial equation in equation 1 below. For the purposes of
plotting C1;5AGplasma as a function of tpreg in the paper, we
assume steady-state levels of C1;5AGplasma as a function of t,
which is physiologically relevant for individuals.
In equation 1, 1,5-AG plasma input rate is assigned as
ki (representing both ingestion and endogenous produc-
tion of 1,5-AG) and is balanced in the steady state by
excretion rate through the kidneys. As seen in Table 1, ki
is approximated as 5 mg/day from Yamanouchi et al.
(1991), who approximated 1,5-AG supplement through
foods as 4.38 mg/day on eight healthy subjects, mean uri-
nary 1,5-AG excretion as 4.76 mg/day (with negligible
excretion into stools), and 0.4 mg/day of de novo synthe-
sis of 1,5-AG suggested in patients without oral supple-
ment of 1,5-AG.
1,5-AG is rapidly repartitioned between plasma and tis-
sue pools, with the fraction of 1,5-AG in the plasma being
proportional to the fraction of plasma mass to total mass
in a given individual. For pregnant individuals, we model
this as a fraction which varies with time in pregnancy
ðf 1;5AGplasma ðtpregÞÞ and is approximated to be independent of
glycemic state (Whittaker and Lind 1993).
1,5-AG is excreted from plasma through the kidneys,
and the rate at which it does so is dependent on both the
glomerular filtration rate (GFR) and on reabsorption in
the glomerular tubules (r). As found via patient data,
glomerular filtration rate changes substantially throughout
pregnancy and is modeled as a function of time in preg-
nancy, GFR(tpreg) described in the results.
High glucose concentrations inhibit reabsorption of
1,5-AG and increase the excretion rate, leading to net
depletion of plasma 1,5-AG. This phenomenon has been
modeled by Stickle and Turk (1997) via equation 2
below, describing reabsorption fraction at normal and
high glucose concentrations:
r
0:998 if ½G\7:4mM
ð0:0026mM1Þ  ½G þ 1:018 if ½G[ 7:4mM

(2)
As seen in Figure 1 and later in Figure 4, we adapt this
model by allowing for the incorporation of time in preg-
nancy into r:r(tpreg, [G]). While glucose concentrations do
fluctuate over the time-span of minutes in both normal
and diabetic individuals, as shown by Stickle et al. (via
their Fig. 2), this short-term fluctuation does not
significantly alter 1,5-AG levels in normal or diabetic
individuals.
As will be shown, the steady-state mass balance model
proposed by Yamanouchi and Akanuma (1994) and
Stickle and Turk (1997) can be expanded to include the
kinetic characteristics of 1,5-AG behavior during diabetic
pregnancy. The implications of the kinetic model for the
use of 1,5-AG monitoring in the evaluation of glycemic
control are discussed.
Fitting physiological data from the
literature
The literature was explored for relevant physiological data
points that would allow us to adapt the pre-established
model for cases of normal pregnancy and diabetic preg-
nancy (GDM/DM). Parameters included factors that were
suggested to strongly affect 1,5-AG concentration in
plasma including GFR, fraction of plasma to tissue mass,
and plasma volume; value change versus time during ges-
tational progression was noted. GFR data for nondiabetic
and diabetic pregnancies were derived from a longitudinal
study by Dunlop (1981) which examined 25 healthy
women during pregnancy using inulin clearance. Plasma
volume for normal pregnancy was derived from Whit-
taker and Lind (1993), a longitudinal prospective study
examining albumin concentration and plasma volume in
69 healthy pregnant women. Fraction of plasma to total
body mass ðf 1;5AGplasma ðtpregÞÞ was derived using data from an
dC1;5AGplasma
dt
¼ f 1;5AGplasma ðtpregÞ 
ki
VplasmaðtpregÞ  GFRðtpregÞ 
C1;5AGplasma
VplasmaðtpregÞ  1 rðtpreg; ½GÞ
 " #
(1)
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investigation by Pipe et al. (1979) which longitudinally
examined 27 women during normal pregnancy utilizing
body composition analysis. Due to the limited availability
of data, we were unable to differentiate between normal
pregnancy and different subtypes of diabetic pregnancy
(GDM/DM) with respect to GFR, plasma volume, and
fraction of plasma to tissue mass.
These data were used to find fits over time in pregnancy
for GFR, plasma volume, and fraction of mass from plasma
using least squares fitting. All error bars represent one
standard deviation. In calculating the error bars for frac-
tional plasma mass, we first calculated the standard devia-
tion of the increase in total body weight for each time
point; the error bars illustrate the reciprocals of these val-
ues. Standard deviations for plasma mass were ignored as
they were not provided in Pipe et al. (1979).
1,5-AG data across weeks of gestation from normal
pregnant individuals and pregnant individuals with
GDM/DM were acquired from a longitudinal study by
Tetsuo et al. (1990), which evaluated serum concentra-
tions of 1,5-AG in 543 normal pregnant women and 75
pregnant women with GDM/DM. These data were used
to compare the mathematical model to observed 1,5-AG
measurements.
Computational modeling & parameter
derivation
The fits from the literature data were utilized as parame-
ters in our ODE system (eq. 1). The ODE was solved
using the ode15s differential equation solver in MATLAB
(Natick, MA). In fitting the ODE to 1,5-AG data, we
minimized the square of the difference using a termina-
tion tolerance for the function value of 1e-5.
Results
Fitting physiological data from the
literature
We mined published data for parameters that were sug-
gested to strongly affect 1,5-AG concentration in plasma
during the gestational period, including GFR, plasma
Figure 1. Compartment model for 1,5-AG. This two-compartment
model describes 1,5-AG dynamics in plasma and tissue over
timeline in pregnancy (tpreg), assuming rapid partitioning between
tissue and plasma pools. The fraction of 1,5-AG in the plasma is
proportional to the fraction of plasma mass to total mass in a given
individual. For pregnant individuals, we model this as a fraction that
varies with time in pregnancy ðf1;5AGplasma ðtpregÞÞ and is approximated
to be independent of glycemic state. The 1,5-AG input rate, ki,
represents both ingestion and endogenous production of 1,5-AG.
1,5-AG is excreted from plasma through the kidneys, and the rate
at which it does so is dependent on both the glomerular filtration
rate, modeled as a function of tpreg, (GFR(tpreg)), and reabsorption
in the glomerular tubules, modeled as a function of tpreg and
glucose concentration, (r(tpreg, [G])). For purposes of dimensional
analysis, ki and GFR were scaled by plasma volume (Vplasma(tpreg)).
See equation 1 and Table 1 for additional details.
Figure 2. Fitting physiological parameters throughout pregnancy. These fits were used in our model for 1,5-AG during normal pregnancy. (A)
Glomerular filtration rate (GFR), using data from 25 nondiabetic pregnant individuals in Dunlop 1981 and fitting to a second-order polynomial
(eq. 3). (B) Plasma volume, using longitudinal data from approximately 69 healthy females throughout seven times in pregnancy (Sacks et al.
2012) and fitting to a sigmoidal curve (eq. 4). (C) Fractional plasma mass, using data from 27 nondiabetic pregnant individuals in Pipe et al.
1979 and fitting to a line (eq. 6). This value was found by dividing the increase in plasma mass at each time point by the total body mass
gained, since the start of pregnancy (eq. 5). Average standard deviations across all available time points visualized in Figure 2 are reported for
each parameter (for fractional plasma mass, the standard deviations are averaged for the three time points during pregnancy, excluding
week 0).
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volume, and fraction of plasma to tissue mass, and found
best fit equations that modeled their change over gesta-
tional time.
To find an expression that adequately fit the overall
GFR data, the individual data series for 25 nondiabetic
patients across four time points (before pregnancy,
16 weeks pregnant, 26 weeks pregnant, and 36 weeks
pregnant) were examined (Dunlop 1981). For most
patients, the GFR trajectory followed a parabolic path
explained by a best-fit equation (eq. 3) (R2 = 0.52),
increasing by a maximum of 1.57-fold, with a peak at
time 27.1 weeks in pregnancy.
GFR ¼ 0:077  tpreg2 þ 4:17  tpreg þ 99:04 ½mL=min
(3)
The plasma volume throughout pregnancy was fit with
a sigmoidal curve (eq. 4) (R2 = 0.998).
796:2
0:62þ 4:4  eð0:21ðtpreg9:2ÞÞ þ 2378 ½mL (4)
The fractional plasma mass represents the fraction of
mass gained since the start of pregnancy attributable to
plasma gain. The increase in plasma mass (DMplasma) and
increase in total body mass (DMtotal) since the start of
pregnancy were derived using data from Pipe et al.
(1979). The fractional plasma mass was calculated by
finding the ratio between the former and the latter
(eq. 5). These calculated values were then fitted to a lin-
ear expression with respect to time in pregnancy (eq. 6)
(R2 = 0.98).
f 1;5AGplasma ¼
DMplasma
DMtotal
(5)
f 1;5AGplasma ¼ 0:006  tpreg þ 0:32 (6)
Modeling 1,5-Anhydroglucitol
Using the fits over time in pregnancy for GFR, plasma vol-
ume, and fractional plasma mass, we used an ordinary differ-
ential equation (eq. 1) to model the plasma concentration of
1,5-AG throughout timeline of pregnancy. Before fitting all
parameters in the model simultaneously to the normal and
diabetic (GDM/DM) pregnancy timeline 1,5-AG data, we
first wanted to understand how each of the main individual
parameters r, ki, and [G] separately affected plasma 1,5-AG
levels throughout gestation. Thus, we performed sensitivity
analysis, iterating across these three parameters individually
while keeping all other parameters constant (Fig. 3). The
modeled 1,5-AG results were superimposed over points
derived from healthy, GDM, and DM patients (Tetsuo et al.
1990) to provide insight on the individual effect of each
parameter on 1,5-AG levels.
Figure 3A, B, and C show the behavior of the model
across different fold changes of parameters ki, r, and [G],
respectively. Since ki represents the input rate of 1,5-AG
into the body, we expect that increased ki co-occurs with
higher 1,5-AG levels in plasma. This matches what is
observed in Figure 3A, where a range of ki values were
examined while keeping the reabsorption fraction
constant at 0.9984. We see that scaling ki similarly scales
1,5-AG levels, with a fourfold increase in ki yielding
approximately a fourfold increase in 1,5-AG, as expected
from the linear relationship between 1,5-AG and ki from
equation 1. A ki of 5 yields a plot that stays within one
standard deviation of the 1,5-AG data for normal
patients, while a ki of 2 yields a plot that stays within one
standard deviation of the 1,5-AG data for DM patients.
However, we would expect the dietary 1,5-AG input levels
to be roughly the same between normal, DM, and GDM
patients (although some research suggests that 1,5-AG
levels may be sensitive to dairy intake) (Koga et al. 2010);
0 10 20 30 40
Weeks in pregnancy
0
5
10
15
20
25
30
35
40
P
la
sm
a 
[1
,5
-A
G
] (
g/
m
L)
Plasma 1,5-AG vs. Time in pregnancy
ki: 2
ki: 3
ki: 5
ki: 8
Data (normal)
Data (DM)
Data (GDM)
0 10 20 30 40
Weeks in pregnancy
0
5
10
15
20
25
30
35
40
P
la
sm
a 
[1
,5
-A
G
] (
g/
m
L)
Plasma 1,5-AG vs. Time in pregnancy
r: 0.98
r: 0.995
r: 0.998
r: 0.9984
r: 0.9988
Data (normal)
Data (DM)
Data (GDM)
0 10 20 30 40
Weeks in pregnancy
0
5
10
15
20
25
30
35
40
P
la
sm
a 
[1
,5
-A
G
] (
g/
m
L)
Plasma 1,5-AG vs. Time in pregnancy
Glucose: 6 mmol/L
Glucose: 7 mmol/L
Glucose: 8 mmol/L
Glucose: 9 mmol/L
Data (normal)
Data (DM)
Data (GDM)
A B C
Figure 3. Sensitivity analysis over parameters in the 1,5-AG model. In each plot, one parameter was changed while the others were held
constant. Superimposed data over time are from Tetsuo et al. 1990 (A) Iterations over ki, keeping the reabsorption fraction (r) at 0.9984. (B)
Iterations over r, keeping ki at 5. (C) Iterations over mean maximal glucose levels, keeping ki at 5. The reabsorption fraction was calculated
using equation 2.
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therefore, we other physiological factors aside from ki are
likely causing this difference.
We then moved on to examine how changes in the
reabsorption fraction could affect the model, keeping ki at
a constant nominal value of 5. As expected, higher reab-
sorption fraction corresponds to higher plasma 1,5-AG
values, as seen in Figure 3B. One observation to note is
that small differences in the reabsorption fraction lead to
large differences at the concentration of 1,5-AG; we see
that an increase in r by 0.003 yields a two- to threefold
increase in 1,5-AG levels, which can correspond to the
difference between a pregnant diabetic patient and a nor-
mal patient. Values of r between approximately 0.998 and
0.9984 correspond to the normal case, while a value of
0.995 corresponds to the pregnant diabetic case.
We wished to directly examine the effect of glucose on
1,5-AG levels through implicit changes in the reabsorp-
tion fraction. From equation 2 we see that for all glucose
concentrations below 7.4 mmol/L, the reabsorption frac-
tion stays at a constant value of 0.9984, and as plasma
glucose concentration rises above 7.4 mmol/L, the reab-
sorption fraction linearly decreases with glucose concen-
tration. We performed iterations on the mean maximal
glucose concentration, keeping ki at a constant value of 5
(reflecting nominal ki in healthy individuals, derived from
Stickle and Turk (1997)). We would predict that as glu-
cose concentration increases above 7.4 mmol/L, 1,5-AG
plasma concentration decreases due to decreased
reabsorption fraction. This prediction matches the results
we see in Figure 3C. Glucose levels below 7.4 mmol/L fall
within the range expected for nondiabetic patients, based
on the superimposed data from Tetsuo et al. (1990). We
see that a glucose level of 9 mmol/L corresponds closely
with the data from pregnant diabetic individuals. Thus,
differences in glucose concentration – through their effect
on the reabsorption fraction – seem to have a large effect
on plasma 1,5-AG concentrations. As expected, pregnant
diabetic individuals have higher plasma glucose concen-
trations than normal individuals, which correspond to
smaller reabsorption fractions and thus lower 1,5-AG
levels.
We further sought to investigate our complete model
across combinations of physiological parameters. In Fig-
ure 4A, we examine 1,5-AG levels for normal pregnancy.
The blue line represents the Adjusted Stickle Model,
which illustrates the model for the default values of the
system (ki = 5, r calculated using eq. 2). For normal preg-
nancy, it is assumed that the glucose level is low enough
such that r stays constant at 0.9984. The red line (Best
Fitted Adjusted Stickle Model) represents our model with
the values of ki and r best-fitted to the 1,5-AG data. The
Adjusted Stickle Model deviates from the mean 1,5-AG
data points around 25 weeks, while the Best Fitted
Adjusted Stickle Model has a low ki (2.73 compared to
the expected 5) and a high r (0.999 instead of the
expected 0.9984). This motivated the re-evaluation of the
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Figure 4. Modifications to the model. Both the normal (A) and the pregnant diabetic cases (B) are considered separately. Each case illustrates
three lines: The blue lines represent the Adjusted Stickle Model, or equation 1 using nominal parameters for ki and a from Stickle and Turk
1997 and adjusting by tPreg for GFR, fractional plasma mass, and plasma volume, while assuming that r is constant with respect to tPreg
(i.e., b = 0, from eq. 7). The red lines represent the Best Fitted Adjusted Stickle Model, or the Adjusted Stickle Model using least squares fitted
values for ki and a, with b = 0. The yellow lines represent modifications of the Best Fitted Adjusted Stickle Model, additionally using least
squares fitted values for b. (A) Normal pregnancy. (B) Diabetic pregnancy. The Adjusted Stickle Model uses [G] = 8.9 mM as a representative
value for the mean maximal glucose concentration in diabetic patients, and ki = 5 at a fixed parameter. The fitted models have r = a-b*
(tpreg-25) –c * [G].
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model with respect to time in pregnancy, and in particu-
lar evaluating the one parameter that did not depend on
tpreg in the Adjusted Stickle Model, r. Using a function of
r that depends on tpreg as in equation 7 (corresponding to
the yellow line in Fig. 4A), where b is equal to 0 before
25 weeks and nonzero after 25 weeks, allows for not only
improved fitting of the pregnancy data, but also physio-
logical values much closer to those used in Stickle and
Turk (1997), with ki = 5.16, r = 0.99825 before 25 weeks,
and r = 0.99825-5.78*105*(tpreg-25) after 25 weeks. This
result suggests that there may be physiological changes
during the third trimester of pregnancy that decrease the
reabsorption fraction.
r ¼ a if tpreg 25weeks
a b  ðtpreg  25Þ if tpreg[ 25weeks

(7)
We then performed analogous analyses to the pregnant
diabetic case, using 1,5-AG data from untreated DM and
GDM patients from Tetsuo et al. (1990). For the unfitted
model (Adjusted Stickle), we used a glucose concentration
of 8.9 mmol/L, from the mean maximal glucose concen-
tration of third trimester type 1 diabetic subjects in an
analysis by Nowak et al. (2013), as we expected the mean
maximal glucose level of an untreated pregnant diabetic
patient to be higher than that for a nondiabetic patient.
In the Best Fitted Adjusted Stickle Model, where r is not
a function of tpreg (red line in plot), the fitted ki value is
high (10.64 compared to the expected 5), and the best-
fitted glucose concentration is low (6.19 mmol/L com-
pared to the expected ~8.9 mmol/L). For the yellow line
(Best Fitted Adjusted Stickle Model, with r(tpreg), in addi-
tion to having r depend on tpreg, we also fixed the value
of ki at 5, assuming that physiologically, ki will not signif-
icantly differ between pregnant diabetic and nondiabetic
subjects. Doing this, we get a fitted glucose value
of 9.5 mmol/L, which is higher than our original value of
8.9 mmol/L but is still within one standard deviation of
the mean maximal glucose levels of diabetics in both sec-
ond and third trimesters of pregnancy (Nowak et al.
2013).
For both the normal and GDM cases, we see that find-
ing the best fit of the model while allowing r to depend
on tpreg after 25 weeks allows us to achieve parameters
closer to expected physiological values.
Discussion
Given the limited analysis of quantitative physiology on
1,5-AG during gestation, the present analysis sought to
create a computational model to better guide interpreta-
tion of measured 1,5-AG in both normal and diabetic
pregnancy. Stickle and Turk (1997) model was recali-
brated for the dynamic biological parameters of gestation
in an attempt to better define the variables affecting
changes in 1,5-AG during gestation. The purpose of this
model is to provide a framework to computationally sim-
ulate the major mechanisms affecting 1,5-AG in human
pregnancy. To the best of our knowledge, we are the first
in the literature to synthesize data from multiple sources
and computationally analyze the mechanisms perturbing
1,5-AG levels during pregnancy.
Herein, we mathematically model 1,5-AG fluctuations
during pregnancy by utilizing the steady-state solution of
a differential equation combined with clinical values from
the literature. Three widely cited physiologic variables
fluctuating during pregnancy include GFR, plasma vol-
ume, and fractional plasma mass (Pitkin 1976; Pipe et al.
1979; Dunlop 1981; Ezimokhai et al. 1981; Whittaker and
Lind 1993; Krzyzanowska et al. 2008). A second-order
polynomial was fitted to GFR, while a sigmoidal curve
was fitted to plasma volume. Fraction of plasma to tissue
mass – representing the fraction of mass gained during
pregnancy due to an increase in plasma volume – were
not explicitly found in the literature, and were extrapo-
lated utilizing other data points and found to linearly
increase with time in pregnancy (Pipe et al. 1979; Whit-
taker and Lind 1993). The best-fit equations were subse-
quently used in equation 1 to simulate 1,5-AG and
compare with 1,5-AG data in normal and diabetic preg-
nancies from the literature (Koga et al. 2010). Limitations
of this methodology include low sample sizes from the
population, since the 1990 study by Tetsuo et al. (1990)
is the only comprehensive study which measured serum
1,5-AG levels during pregnancy in normal and diabetic
females. Thus, additional clinical data regarding 1,5-AG
levels during pregnancy would need to be available for
cross-validation of such a model.
In normal pregnancy, a tight fit was found for
<25 weeks using the same baseline parameters (ki, r) as in
the Stickle Model and adjusting for parameters that varied
with timeline in pregnancy (GFR, Vplasma, f
1;5AG
plasma ); how-
ever, a deviation was seen from the model after 25 weeks
(Adjusted Stickle Model in Fig. 4A). Furthermore, best-
fitting this model (Best Fitted Adjusted Stickle Model in
Fig. 4A) for ki and r results in nonphysiological parame-
ters. However, upon allowing reabsorption fraction to
vary with tpreg after 25 weeks of pregnancy as in equa-
tion 7 (Best Fitted Adjusted Stickle Model with r(tpreg) in
Fig. 4A), we find that not only do we arrive at physiologi-
cal values for ki and r, but we also acquire a better fit to
the 1,5-AG data. Similarly, in diabetic pregnancy
(Fig. 4B), the Best Fitted Adjusted Stickle Model with r
(tpreg) using a fixed physiological ki = 5, results in a best-
fit glucose concentration within 1 SD of the postprandial
glucose concentration for pregnant diabetic cohorts found
in the literature (Nowak et al. 2013). Furthermore, this
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model also results in expected best-fit main effects for r
(a = 0.997), and expected relation of reabsorption frac-
tion with [G] (r ~ 0.00029 * [G]), similar to that found
in diabetics in Stickle and Turk (1997) (eq. 2). Thus, our
mathematical model not only gives us the understanding
that 1,5-AG in nondiabetic and diabetic pregnancy can be
simulated by the two-compartment model with very little
adjustment prior to 25 weeks, but that even minor alter-
ations such as making reabsorption fraction a function of
tpreg after week 25 can achieve a better fit while resulting
in physiological parameters.
One of the insights from our findings is the potential
presence of physiological changes during the third trime-
ster that may affect the reabsorption fraction. Reabsorp-
tion rate may change as a function of time during the
third trimester via biological mechanisms such as: (1)
protein composition in the nephron (Cheung and Lafay-
ette 2013), (2) changes in endogenous production of 1,5-
AG (Tetsuo et al. 1990), (3) shunting of 1,5-AG to fetus
(Boer et al. 2014), and (4) higher insulin requirements
during late pregnancy (Davidson et al. 2016). Future
studies may invest in acquiring additional longitudinal
patient data across renal, hemodynamic, glycemic, and
1,5-AG in individuals with GDM and DM during preg-
nancy to better model 1,5-AG during the full nine-month
course of gestation.
Conclusion
1,5-AG is an informative indicator of intermediate-term
glycemic control especially during the early stages of ges-
tation (Yamanouchi et al. 1996; Buse et al. 2003; Dwor-
acka et al. 2006; Andronesi et al. 2012; Boritza et al.
2014), a risk factor for the development of eclampsia
(Dunlop 1981; Mehta et al. 2012), and has been associ-
ated with altered risk of diabetes independent of HbA1c
and fasting glucose (Fukumura et al. 1994; Hanefeld
et al. 1996; Saito et al. 2014). The purpose of our model
is to clarify how physiological changes during pregnancy
(via GFR, reabsorption, plasma volume, and fractional
plasma mass) affect 1,5-AG level during gestation, build-
ing off of a previous kinetic model for nonpregnant
individuals proposed by Stickle and Turk (1997). The
impact of renal and hemodynamic parameters on 1,5-
AG during the gestational timeline has only been
hypothesized in the literature; here we provide a mathe-
matical support of such physiological factors, motivating
improved clinical use and interpretation of 1,5-AG levels
during pregnancy.
Encouragingly, we find that a simple two compartment
model of 1,5-AG kinetics, with all parameters but reab-
sorption fraction adjusted for time in pregnancy, effec-
tively models 1,5-AG kinetics throughout the first two
trimesters of pregnancy. In particular, we show that the
decrease in mean 1,5-AG levels during normal pregnancy
is an expected result of hemodynamic changes, and that
the fairly consistent and low 1,5-AG levels in diabetic
pregnancy are a result of altered intermediate-term glyce-
mic control. In addition to implementing the basic rec-
ommendations from Stickle and Turk’s kinetic model, we
find that making reabsorption a function of time in preg-
nancy in the last trimester was able to reconcile the 25-
week divergence of the original adjusted model from the
patient data in normal gestation. The visual provided
in Figure 4 may be used to clarify the expected trends in
1,5-AG resulting from hemodynamic changes, aiding in
clinical interpretation of 1,5-AG levels during the course
of pregnancy.
We hope that our mathematical approach can serve as
a preliminary model of 1,5-AG dynamics to motivate
additional investigational research and patient data on the
factors impacting 1,5-AG during pregnancy. Quantitative
models such as this may motivate improved clinical use
and interpretation of 1,5-AG levels during pregnancy.
Acknowledgments
The authors would like to extend their gratitude to Mer-
yem Ok for her insightful comments and support on this
endeavor.
Conflict of Interest
The authors have no relevant affiliations or obligations to
any organization or financial entity with respect to the
research, authorship, and publication of this study.
References
Andronesi, O. C., G. S. Kim, E. Gerstner, T. Batchelor, A. A.
Tzika, V. R. Fantin, et al. 2012. Detection of 2-
hydroxyglutarate in IDH-mutated glioma patients by in vivo
spectral-editing and 2D correlation magnetic resonance
spectroscopy. Sci. Transl. Med. 4:116ra114.
deBoer, A. S., K. Koszka, E. Kiskinis, N. Suzuki, B. N. Davis-
Dusenbery, and K. Eggan. 2014. Genetic validation of a
therapeutic target in a mouse model of ALS. Sci. Transl.
Med. 6:248ra104.
Boritza, K. C., I. C. dos Santos-Weiss, A. da Silva Couto Alves,
R. R. Rea, F. O. Pedrosa, deSouza E. M., et al. 2014. 1,5
Anhydroglucitol serum concentration as a biomarker for
screening gestational diabetes in early pregnancy. Clin.
Chem. Lab. Med. 52:e179–e181.
Buse, J. B., J. L. Freeman, S. V. Edelman, L. Jovanovic, and J.
B. McGill. 2003. Serum 1,5-anhydroglucitol (GlycoMark): a
short-term glycemic marker. Diabetes Technol. Ther. 5:355–
363.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society
2017 | Vol. 5 | Iss. 16 | e13375
Page 9
S. M. Zekavat et al. A Computational Model of 1,5-AG Dynamics During Pregnancy
Cheung, K. L., and R. A. Lafayette. 2013. Renal physiology of
pregnancy. Adv. Chronic Kidney Dis. 20:209–214.
Davidson, J., S. Larson, and D. Reader. 2016. Gestational
Diabetes Basics. International Diabetes Center, St. Louis
Park, MN.
Dungan, K. M., J. B. Buse, J. Largay, M. M. Kelly, E. A.
Button, S. Kato, et al. 2006. 1,5-anhydroglucitol and
postprandial hyperglycemia as measured by continuous
glucose monitoring system in moderately controlled patients
with diabetes. Diabetes Care 29:1214–1219.
Dunlop, W. 1981. Serial changes in renal haemodynamics
during normal human pregnancy. Br. J. Obstet. Gynaecol.
88:1–9.
Dworacka, M., E. Wender-Ozegowska, H. Winiarska, M.
Borowska, A. Zawiejska, M. Pietryga, et al. 2006. Plasma
anhydro-D-glucitol (1,5-AG) as an indicator of
hyperglycaemic excursions in pregnant women with
diabetes. Diabet. Med. 23:171–175.
Ezimokhai, M., J. M. Davison, P. R. Philips, and W. Dunlop.
1981. Non-postural serial changes in renal function during
the third trimester of normal human pregnancy. Br. J.
Obstet. Gynaecol. 88:465–471.
Fukumura, Y., S. Tajima, S. Oshitani, Y. Ushijima, I.
Kobayashi, F. Hara, et al. 1994. Fully enzymatic method for
determining 1,5-anhydro-D-glucitol in serum. Clin. Chem.
40:2013–2016.
Hanefeld, M., S. Fischer, U. Julius, J. Schulze, U. Schwanebeck,
H. Schmechel, et al. 1996. Risk factors for myocardial
infarction and death in newly detected NIDDM: the
Diabetes Intervention Study, 11-year follow-up. Diabetologia
39:1577–1583.
Juraschek, S. P., M. W. Steffes, E. R. 3rd Miller, and E. Selvin.
2012. Alternative markers of hyperglycemia and risk of
diabetes. Diabetes Care 35:2265–2270.
Kilpatrick, E. S., B. G. Keevilt, K. L. Richmond, P. Newland,
and G. M. Addison. 1999. Plasma 1,5-anhydroglucitol
concentrations are influenced by variations in the renal
threshold for glucose. Diabet. Med. 16:496–499.
Kishimoto, M., Y. Yamasaki, M. Kubota, K. Arai, T.
Morishima, R. Kawamori, et al. 1995. 1,5-Anhydro-D-
glucitol evaluates daily glycemic excursions in well-
controlled NIDDM. Diabetes Care 18:1156–1159.
Koga, M., J. Murai, H. Saito, M. Mukai, and S. Kasayama.
2010. Habitual intake of dairy products influences serum
1,5-anhydroglucitol levels independently of plasma glucose.
Diabetes Res. Clin. Pract. 90:122–125.
Krzyzanowska, K., L. Zemany, W. Krugluger, G. H.
Schernthaner, F. Mittermayer, C. Schnack, et al. 2008.
Serum concentrations of retinol-binding protein 4 in
women with and without gestational diabetes. Diabetologia
51:1115–1122.
McGill, J. B., T. G. Cole, W. Nowatzke, S. Houghton, E. B.
Ammirati, T. Gautille, M. J. Sarno, and assay UStotG. 2004.
Circulating 1,5-anhydroglucitol levels in adult patients with
diabetes reflect longitudinal changes of glycemia: a U.S. trial
of the GlycoMark assay. Diabetes Care 27:1859–1865.
Mehta, S. N., N. Schwartz, J. R. Wood, B. M. Svoren, and L.
M. Laffel. 2012. Evaluation of 1,5-anhydroglucitol,
hemoglobin A1c, and glucose levels in youth and young
adults with type 1 diabetes and healthy controls. Pediatr.
Diabetes 13:278–284.
Muggeo, M., G. Zoppini, E. Bonora, E. Brun, R. C. Bonadonna,
P. Moghetti, et al. 2000. Fasting plasma glucose variability
predicts 10-year survival of type 2 diabetic patients: the
Verona Diabetes Study. Diabetes Care 23:45–50.
Nowak, N., J. Skupien, K. Cyganek, B. Matejko, and M. T.
Malecki. 2013. 1,5-Anhydroglucitol as a marker of maternal
glycaemic control and predictor of neonatal birthweight in
pregnancies complicated by type 1 diabetes mellitus.
Diabetologia 56:709–713.
Pipe, N. G., T. Smith, D. Halliday, C. J. Edmonds, C.
Williams, and T. M. Coltart. 1979. Changes in fat, fat-free
mass and body water in human normal pregnancy. Br. J.
Obstet. Gynaecol. 86:929–940.
Pitkin, R. M. 1976. Nutritional support in obstetrics and
gynecology. Clin. Obstet. Gynecol. 19:489–513.
Rowan, J. A., W. Gao, W. M. Hague, and H. D. McIntyre.
2010. Glycemia and its relationship to outcomes in the
metformin in gestational diabetes trial. Diabetes Care 33:9–
16.
Sacks, D. A., D. R. Hadden, M. Maresh, C. Deerochanawong,
A. R. Dyer, B. E. Metzger, et al., and Group HSCR. 2012.
Frequency of gestational diabetes mellitus at collaborating
centers based on IADPSG consensus panel-recommended
criteria: the Hyperglycemia and Adverse Pregnancy
Outcome (HAPO) Study. Diabetes Care 35:526–528.
Saito, N., H. Qiao, T. Yanagi, S. Shinkuma, K. Nishimura, A.
Suto, et al. 2014. An annexin A1-FPR1 interaction
contributes to necroptosis of keratinocytes in severe
cutaneous adverse drug reactions. Sci. Transl. Med.
6:245ra295.
Sermer, M., C. D. Naylor, D. Farine, A. B. Kenshole, J. W.
Ritchie, D. J. Gare, et al. 1998. The toronto tri-hospital
gestational diabetes project. A preliminary review. Diabetes
Care 21(Suppl 2):B33–B42.
Stickle, D., and J. Turk. 1997. A kinetic mass balance model
for 1,5-anhydroglucitol: applications to monitoring of
glycemic control. Am. J. Physiol. 273:E821–E830.
Tam, W. H., M. S. Rogers, T. K. Lau, and M. Arumanayagam.
2001. The predictive value of serum 1,5-anhydro-D-glucitol
in pregnancies at increased risk of gestational diabetes
mellitus and gestational impaired glucose tolerance. BJOG
108:754–756.
Temelkova-Kurktschiev, T. S., C. Koehler, E. Henkel, W.
Leonhardt, K. Fuecker, and M. Hanefeld. 2000.
Postchallenge plasma glucose and glycemic spikes are more
strongly associated with atherosclerosis than fasting glucose
or HbA1c level. Diabetes Care 23:1830–1834.
2017 | Vol. 5 | Iss. 16 | e13375
Page 10
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society
A Computational Model of 1,5-AG Dynamics During Pregnancy S. M. Zekavat et al.
Tetsuo, M., T. Hamada, K. Yoshimatsu, J. Ishimatsu, and T.
Matsunaga. 1990. Serum levels of 1,5-anhydro-D-glucitol
during the normal and diabetic pregnancy and puerperium.
Acta Obstet. Gynecol. Scand. 69:479–485.
The Diabetes Control and Complications Trial Research
Group. 1993. The effect of intensive treatment of diabetes
on the development and progression of long-term
complications in insulin-dependent diabetes mellitus. The
Diabetes Control and Complications Trial Research Group.
N. Engl. J. Med. 329:977–986.
The Diabetes Control and Complications Trial Research Group.
1995. The relationship of glycemic exposure (HbA1c) to the
risk of development and progression of retinopathy in the
diabetes control and complications trial. Diabetes 55:968–983.
UK Prospective Diabetes Study (UKPDS) Group. 1998a. Effect
of intensive blood-glucose control with metformin on
complications in overweight patients with type 2 diabetes
(UKPDS 34). UK Prospective Diabetes Study (UKPDS)
Group. Lancet 352:854–865.
UK Prospective Diabetes Study (UKPDS) Group. 1998b.
Intensive blood-glucose control with sulphonylureas or
insulin compared with conventional treatment and risk of
complications in patients with type 2 diabetes (UKPDS 33).
UK Prospective Diabetes Study (UKPDS) Group. Lancet
352:837–853.
Whittaker, P. G., and T. Lind. 1993. The intravascular mass
of albumin during human pregnancy: a serial study in
normal and diabetic women. Br. J. Obstet. Gynaecol.
100:587–592.
Yamanouchi, T., and Y. Akanuma. 1994. Serum 1,5-
anhydroucitol (1,5 AG): new clinical marker for glycemic
control. Diabetes Res. Clin. Pract. 24(Suppl):S261–S268.
Yamanouchi, T., Y. Akanuma, T. Toyota, T. Kuzuya, T. Kawai,
S. Kawazu, et al. 1991. Comparison of 1,5-anhydroglucitol,
HbA1c, and fructosamine for detection of diabetes mellitus.
Diabetes 40:52–57.
Yamanouchi, T., H. Moromizato, T. Shinohara, S. Minoda, H.
Miyashita, and I. Akaoka. 1992. Estimation of plasma
glucose fluctuation with a combination test of hemoglobin
A1c and 1,5-anhydroglucitol. Metabolism 41:862–867.
Yamanouchi, T., N. Ogata, T. Tagaya, T. Kawasaki, N. Sekino,
H. Funato, et al. 1996. Clinical usefulness of serum 1,5-
anhydroglucitol in monitoring glycaemic control. Lancet
347:1514–1518.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society
2017 | Vol. 5 | Iss. 16 | e13375
Page 11
S. M. Zekavat et al. A Computational Model of 1,5-AG Dynamics During Pregnancy
